Investor News

Idag inleds inlösenperioden av teckningsoptioner av serie TO 2

Idag, den 23 maj 2019, inleds inlösenperioden av de teckningsoptioner av serie TO 2 som emitterades i samband med Phase Holographic Imaging PHI AB:s (”PHI”) företrädesemission av units under sommaren 2018.

Read More

PHI and leading supplier of cell analysis instrumentation sign agreement

Phase Holographic Imaging (PHI) and a major publicly traded international supplier of laboratory equipment and cell analysis instrumentation have entered an agreement aiming to determine the scope and nature of a future partnership. The agreement is a result of discussions between the company management teams, over an extended period time.

Read More

Investerarträff 28 maj 2019

Phase Holographic Imaging, inbjuder till investerarträff för befintliga aktieägare och övriga intresserade tisdagen den 28 maj 2019 klockan 16:30 i bolagets lokaler, Scheelevägen 22 i Lund.

Read More

PHI establish US subsidiary to foster US partnerships

As part of the ongoing expansion of activities on the US market, the Board of Directors of Phase Holographic Imaging (PHI) has initiated the process of establishing a fully owned subsidiary in the US.

Read More

PHI releases App Suite 2 – more apps and greater applicability

App Suite 2 is the second release in a series of planned App Suite releases, developed to provide automated live-cell studies to researchers worldwide in an unprecedented user-friendly workflow, using PHI’s HoloMonitor-technology.

Read More

Chairman Klas Cramborn has passed away after a period of illness

By reason of chairman Klas Cramborn’s death, the Board of Directors of Phase Holographic Imaging (PHI) has decided to appoint Mats Lundwall as acting chairman of the Board. “Klas has meant a lot to PHI’s development. With his strategic skills in combination integrity and humor Klas has led the Board in a very commendable way

Read More

PHI expands European distributor network

System-c bioprocess, Aurogene and Labsoft have recently been appointed to respectively represent Phase Holographic Imaging (PHI) in France, Italy and Poland.

Read More

Interim Report for the third quarter

For the first time, sales during the past 12 months reached 5 MSEK. Since our previous report, much effort has gone into implementing the ambitious market expansion made possible by the capital acquisition this summer.

Read More

Leading life science tools company enters technology assessment agreement with PHI

A major publicly traded life science tools company has entered a technology assessment agreement with Phase Holographic Imaging (PHI). The purpose of the agreement is to assess PHI’s Holo¬Monitor technology for cell biology applications, primarily within immuno-oncology.

Read More

PHI and BioSpherix expand marketing partnership after scientific evaluation

In June 2018, Phase Holographic Imaging (PHI) and BioSpherix Medical entered a collaboration agreement, aiming to co-market the companies’ complementary product lines. BioSpherix develops and market advanced hermetically sealed cell incubators for the control and optimization of cell culture environments.

Read More